Treatment of dopaminergic rat PC12 cells with human immunodeficiency virus, type 1 (HIV-1) Tat protein or tat cDNA inhibited the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme for the dopamine biosynthetic pathway, as well as the production and release of dopamine into the culture medium. Moreover, the Tat addition to PC12 cells up-regulated the expression of the inducible cAMP early repressor (ICER), a specific member of the cAMP-responsive element modulator transcription factor family, in a cAMP-dependent manner. In turn, ICER overexpression abrogated the transcription activity of the TH promoter in PC12 cells, strongly suggesting ICER involvement in Tat-mediated inhibition of TH gene expression. In vivo injection of synthetic HIV-1 Tat protein into the striatum of healthy rats induced a subclinical Parkinson's-like disease that became manifested only when the animals were treated with amphetamine. As early as one week postinjection, the histochemical examination of the rat substantia nigra showed a reduced staining of neurons expressing TH followed by a loss of TH ؉ neurons at later time points. As Tat protein can be locally released into the central nervous system by HIV-1-infected microglial cells, our findings may contribute to the explanation of the pathogenesis of the motorial abnormalities often reported in HIV-1 seropositive individuals.
Isolated parkinsonian features, such as bradykinesia, postural instability, hypomimetic facies, and tremor, are common manifestations of acquired immunodeficiency syndrome (AIDS) (1, 2) . In some occasions, HIV-1-infected 1 patients may present with an illness virtually identical to Parkinson's disease (PD), whereas, more often, they exhibit a striking sensitivity to dopamine (DA) receptor blocking drugs (3, 4) . Of interest, it has also been reported that the cerebrospinal fluid of HIV-1 seropositive patients shows significantly lower levels of DA with respect to HIV-1 seronegative individuals (5) . Of note, a recent study demonstrated that HIV-1 infection per se induces PD, which, thus, may be considered another primary HIV-1-induced syndrome (4) .
As microglial cells and astrocytes are infected with HIV-1, whereas neurons are not infected (6) ; it has been hypothesized that HIV-1 viral proteins locally released by infected cells may produce neuronal dysfunction and/or loss. One HIV-1 protein so implicated is the trans-acting regulatory Tat protein (7) , which has been shown to be expressed in cells obtained from the central nervous system of encephalitic AIDS patients (6) . In vitro and in vivo studies have shown that HIV-1-infected cells (8, 9) can actively release Tat, which displays pleiotropic activities on the survival and function of a variety of bystander uninfected cells, including neuronal cells (10 -20) .
The aim of this study was to investigate whether the HIV-1 Tat protein could play a role in the pathogenesis of the parkinsonian features frequently observed in AIDS patients. As PD is characterized by a slow and protract loss of dopaminergic neurons in the substantia nigra (SN) that project to the striatum, we explored whether Tat was able to modulate the tyrosine hydroxylase (TH) expression in the PC12 dopaminergic cell line. Moreover, because it has been shown that Tat protein is rapidly taken up by intact cells both in vitro (10, 21) and in vivo (22) , we have also explored whether local administration of Tat into the rat striatum could affect the nigro striatal pathway.
EXPERIMENTAL PROCEDURES
Cell Treatment, Plasmids, and Transfections-Rat pheochromocytoma PC12 cells were cultured in DMEM (Life Technologies, Inc.) ϩ 10% horse serum (Life Technologies, Inc.) ϩ 5% fetal calf serum (fetal calf serum, Life Technologies, Inc.). For evaluation of DA release, PC12 cells were serum-starved (DMEM ϩ 0.1% fetal calf serum) for 40 h in 100-mm plates and then: (i) supplemented with 10 -100 ng/ml of synthetic Tat (Technogen, Caserta, Italy) or bovine serum albumin (BSA) (fraction V Chon, Sigma); (ii) transiently transfected with 5 g of the construct pRPneo/tat, allowing the expression of the tat cDNA under the control of the SV40 promoter or with the pRPneo empty vector (14) ; and (iii) stably transfected with the same plasmids described above and cultured under continuous G418 selection, as described previously (14) .
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into a ptk-CAT plasmid, in which the tk promoter was removed; (ii) pCARE1/4tk-CAT, containing the fragment of the ICER promoter corresponding to base pairs Ϫ154 to Ϫ92 cloned into a ptk-CAT plasmid; (iii) pCARE1/2tk-CAT, containing the fragment of the ICER promoter corresponding to base pairs Ϫ154 to Ϫ121 cloned in a ptk-CAT plasmid; (iv) pCARE3/4tk-CAT, containing a fragment of the ICER promoter corresponding to base pairs Ϫ120 to Ϫ92, cloned in a ptk-CAT plasmid; and (v) pCAT and ptk-CAT empty vectors.
For studies on the TH promoter, PC12 cells were transiently cotransfected with 5 g of the expression pCMV-ICER-Ib construct and 5 g of the reporter TH2400CAT plasmid or 5 g of the pCAT empty vector (kindly provided by Dr. C. Tinti, Cornell University, NY). In this group of experiments, forskolin (20 M, Sigma), a potent activator of TH gene expression (24) , was added directly into medium 16 h prior to harvest. All transient transfection experiments were performed using the PerFect transfection kit reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Cell extracts were prepared and tested in CAT assay as described previously (14) .
Determination of the DA Content in and Release by PC12 Cells-At 48 h after Tat treatment or tat transfection, the culture medium of each PC12 cell sample was harvested, filtered, and analyzed for the DA content by high performance liquid chromatography. In parallel, PC12 cells were analyzed either for TH protein and RNA expression or for the presence of dense core granules by transmission electron microscopy. For this purpose, cells were fixed with 2.5% glutaraldehyde PBS for 1 h, post-fixed in 1% OsO 4 in veronal buffer, alcohol dehydrated, and embedded in araldite. Thin sections were collected on nickel grids, stained with uranyl acetate and lead citrate, and analyzed with a Philips CM 10 electron microscope at 80 kV.
cAMP Assay-The cAMP assay was performed using the cAMP assay kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions. Briefly, after 40 h of starvation in DMEM ϩ 0.1% FCS, 100-mm plates of PC12 cells were treated with 100 ng/ml of synthetic Tat, BSA solution (0.1%), or forskolin (20 M) for up to 30 min. Adding the lysis buffer provided by the manufacturer terminated the incubation. The intracellular cAMP content of the samples was measured by enzyme-linked immunosorbent assay and expressed as pM/100 g of proteins.
Analysis of TH Protein, TH mRNA, and ICER mRNA in PC12 CellsFor the analysis of TH protein, Western blot was performed on approximately 10 ϫ 10 6 cells/experimental point. Cells were harvested in 100 l of lysis buffer (without Triton X-100), sonicated, and centrifuged at 100,000 ϫ g for 1 h at 4°C. The supernatants were discharged and the pellets were solubilized in 100 l of lysis buffer containing 0.1% Triton X-100 and centrifuged again at 100,000 ϫ g for 1 h at 4°C. These supernatants were harvested as the particulate fractions. 100 g of proteins were migrated in a 10% acrylamide gel and blotted onto nitrocellulose filter as described previously (14) . Filters were incubated overnight at 4°C with a 1:500 dilution of anti-TH monoclonal antibody or a 1:500 dilution of anti-tubulin monoclonal antibody (Sigma). Specific reactions were revealed with the ECL Western blotting detection reagent (Amersham Pharmacia Biotech).
For the analysis of TH mRNA, a Northern blot was performed starting from total RNA extracted from 10 ϫ 10 6 cells/experimental point with RNAzol (Galveston, TX). 15 g of RNA from each sample were transferred to nylon membranes and hybridized with a digoxigeninlabeled TH DNA probe, represented by the complete cDNA sequence. A XbaI/Pst 780-base pair fragment of glyceraldeyde-3-phosphate dehydrogenase represented control probe.
For the analysis of ICER mRNA, aliquots of PC12 cells were harvested, and RNA was purified using the SV total RNA isolation system (Promega, Madison, WI) following the manufacturer's protocol. Synthesis of first strand cDNA and amplification were performed using an equivalent amount of RNA/each sample as template and the Access reverse transcriptase-PCR system (Promega) following the manufacturers protocol. Primers used for the amplification of ICER were as follows: 5Ј-ATGGCTGTAACTGGAGATG-3Ј (ICER-5Ј-primer) and 5Ј-CTA-ATCTGTTTTGGGAGAGC-3Ј (ICER-3Ј-primer). These primers, designed based on a previously published sequence (25) amplify two bands of approximately 300 base pairs, corresponding to ICER-Ib and ICER-␥-Ib isoforms (24, 25) . The conditions of the amplification, carried out for 40 cycles, were 15 s at 94°C, 15 s at 42°C, and 20 s at 68°C. As a control for DNA contamination, equal amounts of RNA were used for PCR without template retrotranscription. The resulting PCR products were separated on 2% Seakem GTG agarose gel (FMC BioProducts, Rockland, ME) and analyzed by Southern blot hybridization by using an internal oligonucleotide probe spanning the Ib exon of the ICER cDNA (5Ј-GAGGAACTTGAAACCTTGAAAGACATT-3Ј). X-ray films were scanned and evaluated by densitometry. To normalize for the quantity of template in each sample, ␤-actin reverse transcriptase-PCR was carried out by using the rat ␤-actin control primers (CLONTECH, Palo Alto, CA). ␤-actin PCR products were visualized under UV light after staining of agarose gel with ethidium bromide.
In blocking experiments performed with pharmacological inhibitors, PC12 cells were pretreated for 1 h at 37°C with H89 (10 Ϫ6 M) and PD 98059 (10 Ϫ4 M, both from Sigma and dissolved in Me 2 SO) diluted in DMEM medium, whereas control cells were treated with Me 2 SO diluted in DMEM ϩ 0.1% BSA.
Animal Treatment and Histopathological Evaluation-Adult male Wistar rats (200 -250 g) were divided into three groups (at least six animals each) and given: 1) BSA (10 g/each animal) diluted in PBS; 2) synthetic Tat (10 g/each animal) diluted in PBS, 0.1% BSA; 3) 6-OHDA (20 g/each animal; Sigma) diluted in PBS, 0.1% BSA. At the time of surgery, the animals were anesthetized with ketamine/xylazine and placed into a stereotaxic apparatus for the performance of unilateral injection into the left striatum (coordinates: AP-1, L 3, V 4.5 from Bregma) as described (26) . At 1-4 weeks postrecovery, the injected rats were tested for rotational behavior. On the day of testing, rats were individually placed in a cylindrical acrylic cage and left to adapt for 60 min. At that time, the rats were given a subcutaneous injection of amphetamine (5 mg/kg), and rotational behavior was measured for 60 min. One day after the test period, all the animals were anesthetized and perfused transcardially with 4% paraformaldehyde, 0.075 M sodium phosphate, and 1.5% methanol. Free floating sections (25 m) were taken through the striatum and the SN and subjected to cytological staining with blue of toluidine as well as to immunohistochemical analysis for TH expression. For this purpose, slides were incubated overnight at 4°C with the anti-TH monoclonal antibody (Calbiochem) (dilution 1:25 in PBS containing 1% normal rabbit serum). After two washings with PBS, slides were incubated with a biotinylated secondary antibody using the avidin-biotin peroxidase (Vector Laboratories, Burlingame, CA) procedure. The negative controls consisted of normal mouse serum (dilution 1:200) followed by identical second step labeling as above. The intensity of TH staining was quantitatively evaluated by using the Quantimet 500 image analyzer (Leica, Milan, Italy).
Detection of Apoptosis-Apoptosis was evaluated on both histological sections obtained from rat striatum or SN and PC12 cells by using the terminal deoxynucleotidyltransferase-mediated dUTP biotin nick and labeling technique to monitor the DNA fragmentation in situ, following a previously described procedure (27) .
Statistical Analysis-Statistical analysis was performed using the two-tailed Student's t test.
RESULTS

Impaired TH Expression and DA Release in Tat-treated PC12
Rat Pheochromocytoma Cells-The ability of HIV-1 Tat to interfere with TH expression and DA release was first evaluated using the dopaminergic rat pheochromocytoma PC12 cell line, which has been widely employed as a model system for dopaminergic neurons. In fact, once implanted in the striatum, PC12 cells show the ability to attenuate the DA depletion and sensorimotor impairments in rats with parkinsonian symptoms (28) . As high concentrations (M) of extracellular Tat have been reported to induce apoptosis of both primary neurons (16, 18, 19) and PC12 cells (13) , in this group of experiments, Tat was either added at low concentrations (10 -100 ng/ml corresponding to 1-10 nM) or expressed endogenously in transfection experiments. Under our culture conditions, the viability of both Tat-treated and tat-transfected PC12 cells, evaluated by Trypan blue dye exclusion, was constantly Ͼ95% for all the time points examined. Conversely, the percentage of apoptosis in Tat-treated and tat-transfected PC12 cells, analyzed by using the terminal deoxynucleotidyltransferase-mediated dUTP biotin nick and labeling technique, was Ͻ4% in four separate experiments.
A clear-cut decrease in the levels of TH protein as well as in the steady-state TH mRNA was noticed in both tat-expressing (Figs. 1A) and Tat-treated (not shown) cells with respect to control cells. In addition, the spontaneous release in the culture supernatant of high DA levels by PC12 cells was reduced either by the addition in culture of 10 nM extracellular Tat (p Ͻ 0.05) or by a transient (p Ͻ 0.05) or stable (p Ͻ 0.01) transfection with tat cDNA (Fig. 1B) . Of note, tat-expressing PC12 cells also showed a drastic loss of the dense core catecholaminergic granules, as evaluated by ultrastructural analysis (Fig. 1C) . The total number of dense core granules scored in high magnification transmission electron microscopy sections obtained from 50 distinct PC12 cells was 2876 compared with 189 dense core granules counted in transmission electron microscopy sections obtained from 50 tat-transfected PC12 cells.
Tat-mediated Up-regulation of ICER Repressor in PC12 Cells through a cAMP-dependent Pathway-Because it has been previously shown that a specific member of the cAMP-responsive element modulator (CREM) family of transcription factors, the ICER (29) efficiently represses the transcription activity of the TH gene promoter under both basal and protein kinase A-stimulated conditions (24); we next investigated the potential role of ICER in mediating the Tat-induced down-regulation of TH gene expression in PC12 cells (Fig. 2A) . As expected (24), background levels of ICER mRNA were observed by reverse transcriptase-PCR in PC12 left untreated. On the other hand, in the presence of 10 nM Tat, significant amounts of ICER mRNA were clearly detectable at 4 h of treatment and progressively increased reaching maximal levels after 8 -24 h. In the presence of the positive control forskolin, the peak expression of ICER was observed after 8 h with a decline thereafter.
In the next group of experiments, we sought to investigate whether the Tat-mediated up-regulation of ICER occurred at the transcription level. For this purpose, PC12 cells were cotransfected with tat cDNA plus a series of constructs containing the ICER promoter in front of CAT. As shown in Fig. 2B , Tat transactivated with similar efficiency pICER-CAT, which contains the whole ICER promoter, and pCARE1/4tk-CAT, which encodes a cluster of four CRE-like elements (termed cAMP-autoregulatory elements, CAREs) located in the ICER promoter (23) . On the other hand, tat less efficiently transactivated pCARE1/2tk-CAT and pCARE3/4tk-CAT, which contain only two of the four CARE elements. These findings suggested that all the CARE elements significantly contributed to the Tat-mediated transactivation of ICER.
Previous studies have demonstrated that Tat can either act directly at the nuclear level (10, 21, 22) , modulating the expression of cellular and viral genes (reviewed in Ref. 30 ), or it can activate various signal transduction pathways, including cAMP/protein kinase A (31) and extracellular signal-regulated kinase/mitogen-activated protein kinase (32, 33) . Interestingly, both of these pathways have been shown to activate ICER repressor in PC12 cells (34, 35) . To evaluate whether and which of these pathways were involved in triggering ICER induction in PC12 cells, we have used H89 and PD98059, two pharmacological inhibitors specific for protein kinase A and extracellular signal-regulated kinase/mitogen-activated protein kinase pathways, respectively. Reverse transcriptase-PCR analysis showed that only H89 abrogated the levels of Tat-stimulated ICER (Fig. 3A) , whereas no reproducible variations were noticed in the presence of PD98059. Moreover, we found that Tat induced a rapid and transient increase in the intracellular cAMP levels in PC12 cells (Fig. 3B) , with an activation kinetic that was consistent with a role in ICER induction (34) .
To test directly whether ICER can regulate TH transcription in the PC12 cell clone used in this study, the reporter plasmid TH2400CAT and the expression plasmid pCMV-ICER-Ib (24) were co-transfected into PC12 cells, and CAT activities were measured. Co-transfection of the ICER expression construct significantly (p Ͻ 0.05) diminished CAT activity (Fig. 4) . ICERmediated repression of forskolin-stimulated transcription of the TH construct was even more dramatic (p Ͻ 0.01) than repression of basal transcription. Tat (lanes 1-3) or 100 ng/ml synthetic Tat (lanes 4 -6) in the absence (lanes 1 and 4) BSA, used as negative control, or 6-OHDA, used as positive control (26) .
Induction of a Subclinical Parkinson's-like Disease in
Clinically, the rats did not show gross motorial abnormalities unless treated with amphetamine (5 mg/kg). This treatment, which enhances the release of DA at the striatal level, significantly (p Ͻ 0.01) increased the frequency of rotations ipsilateral to the injection side in rats treated with Tat or 6-OHDA, but not in animals injected with BSA, from week 1 post-injection onward (Fig. 5) .
At various time points postinjection, the animals were sacrificed. Histological sections were performed through the rostrocaudal extent of the striatum and midbrain and stained for TH immunoreactivity to identify nigral DA neurons and fibers. The first signs of ongoing degenerative changes in the SN of Tat-treated animals, observed at 1 week postinjection, were a loss of TH immunoreactivity in both nigral DA neuron cell bodies and fibers on the injected side (Fig. 6A) . The mean TH staining of 70 cell bodies in the lesioned and unlesioned side was 41.7 and 89.2 arbitrary units, respectively (p Ͻ 0.01). At later time points (4 weeks postinjection) a loss of TH ϩ neurons and fibers characterized the lesioned side of Tat-injected (Fig.  6B ) and 6-OHDA-injected (Fig. 6C ) rats, whereas BSA-injected (Fig. 6D ) animals did not show any difference between the lesioned and unlesioned side.
In the effort to evaluate whether the degenerative changes occurring at the level of SN of Tat-and 6-OHDA-injected rats were due to an increase of apoptosis, we applied the terminal deoxynucleotidyltransferase-mediated dUTP biotin nick and labeling technique to histological sections. Despite the degenerative features characterizing SN TH ϩ neurons in both Tatand 6-OHDA-injected animals, we were unable to observe any significant increase of apoptosis over background levels (Ͻ1.5%) in the lesioned versus the unlesioned side in either Tat-or 6-OHDA-injected animals. Although 6-OHDA (36, 37) and Tat (13, 16, 18, 19) are both able to induce neuronal apoptosis in vitro, similar negative findings in terms of terminal deoxynucleotidyltransferase-mediated dUTP biotin nick and labeling ϩ cells were previously reported by other authors, who analyzed the degree of apoptosis in histological sections obtained from the striatum and SN of 6-OHDA-treated animals (38) . DISCUSSION The findings obtained in this study in both in vitro and in vivo models strongly suggest that HIV-1 Tat protein induces a selective block of TH gene expression and DA release in dopaminergic neurons.
TH catalyzes the first and rate-limiting step in catecholamine biosynthesis (39) . In adult mammals, TH expression is confined to a small number of neuronal groups in the central nervous system and to the neurons of the sympathetic nervous system and neuroendocrine chromaffin cells of the adrenal medulla in the periphery. Levels and activity of the enzyme are finely and differentially regulated in these cells by a large variety of pharmacological and physiological stimuli. Modulation of TH activity occurs at the protein level via phosphorylation of the enzyme (40) and at the gene expression level via transcriptional changes (41) . In vitro experiments with reporter gene constructs have shown that very proximal cisacting elements play important roles in functional regulation of TH gene transcription (42) (43) (44) . Although conflicting data exist, probably related to cell line differences, the cAMP-responsive element, located from 38 to 45 base pairs upstream of the initiation site, appears to be crucial for both basal and cAMPinduced transcription of the TH gene (42, 44) .
The experiments performed on PC12 cells allowed us to establish that extracellular Tat inhibited the TH gene expression through a strong induction of the potent transcriptional repressor ICER, which serves as a general negative regulator of the cAMP-response element-binding protein and CREM families of transcription factors as well as other related bZip family members (29) . CREM is a multiexonic gene that encodes both activators and antagonists of cAMP-inducible transcription by differential splicing. All CREM isoforms are generated by two different promoters named P1 and P2. Initiation at intronic promoter P2 allows the transcription of ICER, which, compared with the previously described CREM isoforms, consists of only the bZip DNA binding dimerization domain. Importantly, the P2 promoter is strongly cAMP inducible and elicits an immediate early response to induction of cAMP pathway (34) . The bZip domain directs specific ICER binding to a consensus cAMP-responsive element. ICER is able to heterodimerize with cAMP-response element-binding protein and thus to function as a dominant repressor of cAMP-induced transcription. Moreover, ICER induction is transient by virtue of negative autoregulation by the same ICER proteins on four tandemly repeated cAMP-responsive elements in the P2 promoter. High levels of inducible ICER expression have been reported in neuroendocrine tissue, such as the pineal, pituitary, thyroid, and adrenal glands (29) as well as in T cells (25) .
The role of ICER in inhibiting the TH gene expression in PC12 cells was demonstrated by co-transfection experiments in which both the basal and forskolin-induced transcriptional activity of the TH promoter were significantly reduced in the presence of ICER. Similar observations have been previously made by Tinti et al. (24) on various dopaminergic cell types. Although we cannot exclude that Tat activates ICER in PC12 cells through internalization (10, 21, 22) and direct interaction with nuclear transcription factors (45) (reviewed in Ref. 7) , the rapid elevation of cAMP following the exposure to extracellular Tat together with the ability of the pharmacological inhibitor H89 to abrogate the Tat-induced ICER expression strongly suggests that Tat may act through a cAMP/protein kinase A-dependent pathway. Moreover, the ability of relatively low concentrations (1-10 nM) of extracellular Tat to inhibit TH expression in the absence of cell death clearly indicates that the Tat-mediated down-regulation of TH via ICER is a specific phenomenon.
Histopathological studies, demonstrating the presence of high concentrations of viral proteins in the striatum of HIV-1 seropositive patients coupled to abnormalities of the pars compacta of the SN even in the absence of clinical evidence of parkinsonism (46, 47) , corroborate the physiopathological implications of our findings obtained in both a cell and an animal model. In this respect, it has been recently shown that Tat can easily across the blood-brain barrier (48) . As detectable levels of Tat protein have been demonstrated to be present in the serum of HIV-1 seropositive individuals (49) , it is possible that also systemic Tat may be introduced into the central nervous system. Moreover, the present demonstration that Tat protein is likely involved in the pathogenesis of the parkinsonian features or overt PD in HIV-1 seropositive individuals strengthens the potential usefulness of a Tat vaccination strategy (9, 30, 50 -52) devoted to protect HIV-1 seropositive asymptomatic carriers from the frequent occurrence of motorial abnormalities. 
